SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
A major trial challenges conventional wisdom on anticoagulation for atrial fibrillation patients at intermediate stroke risk
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 5.
Source diversity sample: Medical Xpress · TCTMD.com · MedPage Today · HCPLive · News-Medical · Medscape · American College of Cardiology.
How this dossier is built: methodology · AI policy · corrections.
Where it stands
A new trial has found that direct oral anticoagulants (DOACs) reduce the risk of stroke in atrial fibrillation (AFib) patients at intermediate risk for stroke. This contradicts current guidelines, which typically reserve anticoagulation for higher-risk patients. The SINGLE-AF trial, presented by the American College of Cardiology, compared DOAC therapy with no anticoagulation.
The trial's results have sparked immediate interest in the medical community. MedPage Today, HCPLive, News-Medical, and Medscape all noted the significance of the findings. The trial's results suggest a potential shift in how AFib patients at intermediate risk are managed.
The American College of Cardiology presented the trial's findings. The trial's results may influence future guidelines and clinical practices. The medical community will be watching for further analysis and potential updates to treatment protocols.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.
Sources (7)
- People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds Medical Xpress · 15h ago
- DOACs Benefit AF Patients With Intermediate Stroke Risk: SINGLE-AF TCTMD.com · 15h ago
- First Major Trial Win for Contemporary DOACs in Lower-Risk Afib MedPage Today · 15h ago
- SINGLE-AF: Oral Anticoagulants Reduce Risk of Stroke in Patients With AF HCPLive · 15h ago
- Oral anticoagulants benefit patients with atrial fibrillation at intermediate stroke risk News-Medical · 15h ago
- DOACs Benefit AF Patients With Intermediate Stroke Risk Medscape · 15h ago
- SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke American College of Cardiology · 15h ago
Answered
What is the SINGLE-AF trial?
The SINGLE-AF trial is a major study that compared the use of direct oral anticoagulants (DOACs) with no anticoagulation in atrial fibrillation (AFib) patients at intermediate risk for stroke.
What are the implications of the SINGLE-AF trial's findings?
The findings suggest that DOACs may be beneficial for AFib patients at intermediate stroke risk, potentially leading to changes in clinical guidelines and practices.
Which outlets have covered the SINGLE-AF trial?
The trial has been covered by MedPage Today, HCPLive, News-Medical, Medscape, and the American College of Cardiology.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
From around our network
- A CAR T-Cell Trial Just Put 3 of 6 Arthritis Patients in Remission daybreakwire.com
- Xylitol Sweetener Linked to Increased Risk of Heart Attack and Stroke world-today-news.com
Related trends
Please Tell Me Red Wine Is Good For Me
A new study has reignited debate on the health benefits of red wine, with some outlets claiming it's good for the heart.
This Habit Could Lower Your Risk of Heart-Related Death by 39%, Study Says
Choosing stairs over elevators may slash heart‑death risk by 39%, sparking a wave of health‑focused lifestyle advice.
A Third Hidden Driver of High Blood Pressure Has Been Discovered
Researchers have identified a third, previously unknown driver of hypertension, marking a potential shift in how medical professionals approach blood pressure.
Heart rate holds vital clues about your health and lifespan
Your heart rate may reveal more about your health and longevity than you think.
Scientists Tracked Cannabis Users’ Hearts Day by Day—One Finding Stood Out
A new study has revealed unexpected effects of cannabis on heart health, sparking widespread interest and debate.
Drug Taken for Common Condition May Be Slowing Alzheimer’s Decline
A common blood thinner may slow cognitive decline in Alzheimer’s patients with atrial fibrillation.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.